• BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine

  • Apr 4 2024
  • Length: 4 mins
  • Podcast

BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine By cover art

BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine

Listen for free

View show details

  • Summary

  • Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
    Show more Show less
activate_primeday_promo_in_buybox_DT
Physical Illness & Disease Hygiene & Healthy Living
Show more Show less

What listeners say about BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available